Introduction
Ephedrine (2-methylamino-l-phenyl-l-propanol) is a naturally occurring alkaloid still extensively used for the treatment of bronchial asthma and upper respiratory tract disorders.
Herxheimer (1946) showed that patient sensitivity to this drug varied significantly and that a proportion of patients developed tolerance to the bronchodilator effects on repeated dosing.
The pharmacokinetics of ephedrine in man have been deduced from urinary measurement made in normal subjects under controlled conditions (Wilkinson & Beckett, 1968a; Welling, Lee, Patel, Walker & Wagner, 1971) . A specific assay has been developed (Pickup & Paterson, 1974) in order to monitor plasma levels and study the pharmacokinetics of ephedrine following oral dosing with ephedrine in asthmatic patients. Studies have been performed in patients treated both acutely and chronically in order to investigate whether patient sensitivity and the development of tolerance could be related to specific changes in the disposition of ephedrine in the body.
Ephedrine is commonly given in a compound tablet such as Franol (Winthrop) which contains theophylline (120 mg), phenobarbitone (8 mg) and ephedrine hydrochloride (11 mg) for the treatment of asthma. Kinetic studies were carried out using one such combination (Tablet 4332, (ephedrine hydrochloride (10 mg), theophylline (125 mg) and phenobarbitone (7.5 mg)), Boots Company Limited) and using ephedrine alone in doses equivalent to that normally found in a compound tablet to investigate whether ephedrine disposition is affected by co-administration of these other drugs.
Methods

Subjects
Ten hospital outpatients, ranging in age from 25-51 years and receiving bronchodilator therapy (normally salbutamol) until the day preceding the investigation, volunteered for the studies. The one patient receiving ephedrine medication was asked to stop this 2 weeks prior to the investigation. All subjects were asked to minimize food and fluid intake on the morning of each study (e.g. fruit juice and a slice of toast), and at least 4 h elapsed after drug administration before lunch was taken.
Materials
(a) An oral dose of (-)-ephedrine hydrochloride (22 mg) was given in solution before (Study Al) and after (Study A2) 2 weeks' treatment with ephedrine hydrochloride (11 mg three times a day), and (b) Two tablets 4332 were given before (Study B3) and after (Study B4) 2 weeks' treatment with one tablet three times a day. A period of at least 2 weeks was allowed between (a) and (b) during which no ephedrine medication was prescribed. The studies were carried out on each of ten patients; one patient (J.H.) withdrew, however, after Study A.
Plasma and urine collections
Ephedrine plasma levels were monitored in all studies; blood samples were drawn into lithium heparin tubes at approximately the following times for each study: 0 (i.e. the blank determination), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 hours.
Sufficient blood was taken to allow separation of the plasma into 2 x 3 ml portions. For Studies Al and B3, 36 h urine samples were collected.
Analysis of plasma and urine ephedrine Plasma samples were assayed by gas chromatography following ether extraction (Pickup & Paterson, 1974) . Urine samples were assayed using a similar method modified to allow for the higher ephedrine concentrations obtained in urine. No attempt was made to measure urine or plasma levels of norephedrine, the major metabolite in man.
Pharmacokinetic assessment of data Drug body level data can, in most circumstances, be assigned to either a one-or two-compartment open model (Notari, 1971; Reigelman, Loo & Rowland, 1968; Welling et al., 1971) . Pharmacokinetic assessment of the current data was carried out as described in the appendix, using both graphical and computer techniques.
Statistical analysis of data
The significance of any interstudy differences in calculated pharmacokinetic parameters within individuals was examined using a two-tailed paired t-test; the Student's t-distribution was used to test the null hypothesis that the average difference between individual pairs of results was zero. Linear least squares regression analyses (Hewlett-Packard programmable calculator 981 0A) were performed to establish the significance of any correlation between calculated pharmacokinetic parameters.
Results
A typical plasma profile, measured as ng base/ml plasma at time t h, following dosage with two compound tablets is shown (Figure 1 ). (N N (N N (N (N 0 (N (N (N (N N (N (N N plasma clearance, rate constant and time of peak plasma level comparing data from: -(a) Acute and chronic ephedrine studies (Tables 1 and 2 respectively). (b) Acute ephedrine and acute compound tablet studies (Tables 1 and 3 ).
(c) Acute and chronic compound tablet studies (Tables 3 and 4 (Wilkinson & Beckett, 1968b (Tables 14) are rough  estimates only (see Appendix) . However, the conclusion that the lag time, absorption rate constant and time of peak concentration are not significantly different whether the ephedrine is in solution or in tablet form is compatible with the reported rapid tablet disintegration and high drug solubility (see above), i.e. the dissolution process appears not to be rate limiting.
The lack of any significant intra-subject difference in calculated pharmacokinetic parameters before or after chronic treatment whether the ephedrine was given alone or in combination with theophylline and phenobarbitone implies that tolerance to the bronchodilator doses used in the present study, if it occurs, is not related to changes in ephedrine disposition in the body but is more probably due to pharmacodynamic changes.
Seven of the patients in the compound tablet study, B4, had half-lives which were shorter than in Study B3 (Tables 3 and 4 ). The mean difference, however, was not statistically significant. In many cases, the faster elimination after chronic treatment with tablet 4332 could be attributed to a greater plasma clearance rather than a decrease in volume of distribution. No comparable decrease was evident in comparing T_ values calculated for the studies with ephedrine alone (Al and A2, Tables 1 and 2 ). It may be deduced therefore that multiple dosing with a preparation containing theophylline or more probably phenobarbitone could influence ephedrine clearance, for example through enzyme induction, and this might become significant if the tablet dosing during chronic treatment were increased above that used in the present study.
Since concurrent drugs used between the studies were limited to small doses of bronchodilator aerosol drugs with subsequent minimal plasma levels, the possibility of drug interaction producing changes in pharmacokinetic parameters is unlikely. Despite the similarity in diet prior to each study, the large inter-subject variations recorded in the pharmacokinetic parameters and with few exceptions their independence of body weight, emphasize the difficulty in formulating standard dosage regimes. In addition there is a large inter-subject variation in the plasma level necessary to cause adequate bronchodilatation (May, Pickup & Paterson, 1975) . Estimates of the maximum and minimum plasma levels during chronic treatment (Table 5) indicate a minimum range of 10-58 and a maximum range of 39-106 ng ml-'. The 
Appendix
Calculation of pharmacokinetic parameters from the concentration-time profile Two methods, one graphical and one using a computer, were used to assess each concentrationtime profile.
(1) Graphical method Linear least squares regression analysis (Hewlett-Packard Programmable Calculator) was used to obtain the line of closest fit to the logarithms of the experimentally obtained data points of the terminal exponential phase (e.g. Figure 2 , line 1). If the maximum recorded concentration (peak plasma level) was not significantly above this regression line, e.g. Figure 2 , the pharmacokinetic parameters were estimated according to one-compartment kinetics: -One-compartment model:-The rate constant for elimination of drug from the entire body wnicn represents tne area from t = 8 -* o. C8 iS the ephedrine plasma concentration at t = 8 h as predicted by the regression line.
The volume of distribution, Vd, was calculated using Equation 4:-
The absorption rate constant, kabs, was obtained from the gradient, G, of the regression line drawn through the feathered points (e.g. Figure 2 , line 2) according to Equation 5:-kabs = -G/2.303
Equation 5 In the acute studies, Al and B3, the lag time, to, was taken as the time at which the regression lines (e.g. Figure 2 , lines 1 and 2) intersect.
It should be noted that estimations of kabs and to are subject to error due to the technique of 'feathering' itself and the lack of data points in the absorptive phase of each profile. Estimations were, however, carried out where possible for completeness.
Two-compartment model:-In those concentration-time profiles where the peak plasma level lay significantly above the regression line drawn through the terminal data points, i.e. where a distribution phase was evident, the half-life, volume of distribution and plasma clearance were estimated according to two-compartment theory (Notari, 1971 Biological availability, f
The theoretical aspects of bio-availability have been discussed by Gibaldi, Boyes & Feldman (1971) and by Rowland (1972) . For (Wilkinson & Beckett, 1 968b) .
The availability from tablet form (Studies B3 and B4) relative to that from solution was calculated from the relative areas under the mean plasma concentration versus time profiles, omitting data from patient J.H. such that profiles from equivalent sample numbers could be compared. The areas under these profiles (calculated graphically), the corresponding half-lives and the availability, calculated using Equation 9 are presented in Table 6 . The availability from tablet form is given by:- where Atab and Asohn are the areas under the plasma concentration-time profiles (t = 0 -O oo) after oral administration of equivalent doses of drug given in tablet form and solution respectively to the same group of subjects. The equation is valid only where the initial (t = 0 h) concentrations and elimination rate constants after solution and tablet dosage are comparable (see Table 6 ) and where the availability from solution is 100%. A mean of the two estimations of f (Table 6 ) was used in subsequent calculations for the tablet studies.
Calculation of approximate peak and through plasma leves * during the two weeks' chronic treatment Assuming one-compartment kinetics and a rapid absorption of drug, the approximate peak plasma level (Pma5, 
